Group 1 - The core viewpoint is that the innovative drug sector is experiencing a resurgence, with notable performances from companies like Sanofi and the launch of Heng Rui Pharmaceutical's H-shares in Hong Kong [1][3] - The Tianhong Innovative Drug ETF has seen a continuous increase for seven days, indicating strong investor interest in the innovative drug sector [1][2] - Heng Rui Pharmaceutical has set its H-share issuance price at HKD 44.05, which is the upper limit of the expected price, reflecting positive market sentiment towards A-share companies listing in Hong Kong [1] Group 2 - The Biopharmaceutical ETF closely tracks the Guozheng Biopharmaceutical Index, which includes the top 30 companies in the biopharmaceutical industry based on market capitalization and liquidity [2] - The Tianhong Innovative Drug ETF tracks the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug 50 Index, which selects 50 leading innovative drug companies across three markets [2] - The innovative drug sector is expected to remain a core focus for the pharmaceutical industry, supported by policy backing and increasing global competitiveness [3]

点评：诺诚健华坦昔妥单抗获批是中国首个治疗复发/难治性弥漫性大B细胞淋巴瘤的CD19单抗，填补 了该靶点治疗空白。作为联合疗法核心药物，其为不适合干细胞移植的患者提供了新选择，凸显精准医 疗价值。此次获批不仅强化了公司在血液瘤领域的竞争力，更推动了中国淋巴瘤治疗与国际接轨。 NO.2 科兴制药创新药GB18注射液获得美国FDA新药临床试验许可 NO.1 诺诚健华注射用坦昔妥单抗上市申请获批 5月21日，诺诚健华发布公告，公司收到国家药品监督管理局的通知，坦昔妥单抗（tafasitamab）联合 来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的上市申请获得批准。这是中国首个获批治疗该病症的 CD19单抗，标志着公司在血液瘤领域的重要进展。公告中提到，坦昔妥单抗是一款靶向CD19的单克隆 抗体，适用于不适合自体干细胞移植的成人患者。 北京万东医疗科技股份有限公司董事会于近日收到公司董事长胡自强先生的书面辞职报告，胡自强先生 因个人原因辞去公司董事长、董事会战略委员会委员、董事会薪酬与考核委员会委员职务，辞任生效后 将不再担任公司任何职务。同意选举马赤兵为第十届董事会董事长。截至目前，马赤兵未持有公司股 份，除担任控 ...

Group 1 - The 21st China (Shenzhen) International Cultural Industries Fair will be held from May 22 to 26, with a significant "policy package" to support six key areas for high-quality cultural industry development [2] - The European Union plans to impose handling fees on small packages entering the EU, with China's Ministry of Foreign Affairs advocating for a fair and transparent business environment for Chinese enterprises [2] - China and the ten ASEAN countries have completed negotiations for the China-ASEAN Free Trade Area 3.0, adding nine new chapters including digital economy and green economy [2] Group 2 - International gold prices rebounded on May 21, with domestic gold jewelry prices surpassing 1,000 yuan per gram, with notable increases from major retailers [3] - Several banks, including Ping An Bank and CITIC Bank, have lowered deposit rates, particularly for medium- and long-term deposits, with some banks suspending five-year term deposits [3] - A surge in A-share buyback and increase plans has been observed, with 394 companies announcing such plans since the second quarter of 2025, a rise of over 60% compared to the first quarter [3] Group 3 - The Hong Kong Hang Seng Index closed up 0.62%, with BYD shares rising over 4% to a new historical high, and southbound funds net buying exceeding 1.4 billion HKD [4] - UBS noted a growing international interest in Chinese assets, highlighting the strategic importance of the Chinese stock market for global investors seeking excess returns [4] Group 4 - Baidu reported Q1 revenue of 32.452 billion yuan, a 3% year-on-year increase, with a notable 42% growth in Baidu Smart Cloud [5] - Xpeng Motors achieved Q1 revenue of 15.81 billion yuan, a 141.5% year-on-year increase, with a projected delivery volume of 102,000 to 108,000 units in Q2 [5] - Weibo's Q1 revenue remained stable at 396.9 million USD, with a 12% year-on-year increase in adjusted net profit [5] Group 5 - The stock price for Naxin Microelectronics was set at 163.15 yuan per share, with a subscription rate of 1.29 times from institutional investors [6] - The U.S. stock market saw declines across major indices, with significant drops in Chinese concept stocks such as iQIYI and Baidu [6]

证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-081 江苏恒瑞医药股份有限公司 公司已确定本次H股发行的最终价格为每股44.05港元（不包括1%经纪佣金、0.0027%香港证券及期货事 务监察委员会交易征费、0.00565%香港联交所交易费及0.00015%香港会计及财务汇报局交易征费）。 公司本次发行的H股预计于2025年5月23日在香港联交所主板挂牌并开始上市交易。 特此公告。 江苏恒瑞医药股份有限公司董事会 2025年5月21日 关于境外上市外资股（H股）公开发行价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）正在进行发行境外上市外资股（以下简称"H股"）股票 并在香港联合交易所有限公司（以下简称"香港联交所"）主板挂牌上市（以下简称"本次发行上市"）的 相关工作。 本次拟发行的H股股份的认购对象仅限于符合相应条件的境外投资者及依据中国相关法律法规有权进行 境外证券投资管理的境内证券经营机构和合格境内机构投资者及其他符合监管规定的投资者。因此，本 ...

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]

Group 1: IPO Market Overview - The Hong Kong stock market is experiencing a new wave of IPO activity, with total fundraising reaching HKD 145 billion in the past year, a year-on-year increase of 2.7 times [1][2] - The top ten IPOs, primarily from mainland companies, contributed 75% of the total fundraising, with notable leaders being CATL and Midea Group [2][3] - As of May 21, 2025, 76 new stocks have been listed, with 23 companies going public this year alone, raising a total of HKD 653 billion [2] Group 2: Key Players and Fundraising - CATL and Midea Group led the fundraising efforts with HKD 410 billion and HKD 356.66 billion respectively, marking them as the top fundraisers for 2024 and 2025 [2][4] - Other significant players in the second tier include Horizon Robotics, SF Express, and China Resources Beverage, each raising over HKD 50 billion [2][4] - The third tier consists of consumer-related companies like Mixue Group and Chifeng Gold, raising between HKD 20 billion and HKD 40 billion [3][4] Group 3: Globalization and Strategic Moves - Chinese companies are accelerating their global expansion through the "A+H" dual capital market strategy, which is crucial for their international growth [5][6] - Leading companies in various sectors, including pharmaceuticals and consumer electronics, are planning to list in Hong Kong to enhance their global presence [6][7] - The automotive sector is also seeing increased activity, with companies like Seres and Chery Motors planning to raise funds through IPOs in Hong Kong [8] Group 4: Capital Inflows and Market Dynamics - The weakening US dollar has led to increased capital inflows into the Hong Kong market, as investors seek to buy Chinese assets [9][10] - The Hong Kong Monetary Authority has injected over HKD 1.16 billion into the market to support the Hong Kong dollar, reflecting strong demand for stocks [9] - The successful IPOs of companies like CATL have created a "money-making effect," encouraging more mainland companies to pursue listings in Hong Kong [10] Group 5: Regulatory Environment - The Hong Kong regulatory framework is evolving to facilitate the listing process for mainland companies, including the introduction of a "special line" for tech and biotech firms [11][12] - Recent changes have lowered the minimum requirements for H-share listings, making it easier for companies to access the Hong Kong capital market [12]

公开资料显示，工银前沿医疗股票C基金成立于2020年11月23日，截至2025年3月31日，工银前沿医疗 股票C规模13.80亿元，基金经理为赵蓓。 金融界2025年5月21日消息，工银前沿医疗股票C(010685) 最新净值2.9140元，增长1.53%。该基金近1个 月收益率4.11%，同类排名420|1001；近3个月收益率9.30%，同类排名81|988；今年来收益率13.47%， 同类排名116|978。 工银前沿医疗股票C股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、XD药明康（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2 ...

Group 1 - Heng Rui Medicine has set the final price for its H-share issuance at HKD 44.05 per share, with expected listing on May 23, 2025 [1] - Vanke A has signed a borrowing contract with Shenzhen Metro Group for RMB 4.2 billion, using up to RMB 6 billion of Wanwu Cloud stock as collateral [2] - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international competitiveness [3] Group 2 - Shanghai Laishi's controlling shareholder, Haiyingkang, plans to increase its stake in the company by investing between RMB 250 million and RMB 500 million [4] - Wangzi New Materials' controlling shareholder sold 1.11 million shares, accounting for 0.29% of the total share capital, amid the "controlled nuclear fusion" concept [5] - Huashi Technology's actual controller, Ye Jianbiao, has had his detention extended by three months, but the company's operations remain normal [6] Group 3 - Sichuan Gold's major shareholders plan to reduce their stakes by 2.5% and 3% respectively, citing personal funding needs [7] - Naxinwei has set the inquiry transfer price at RMB 163.15 per share, with full subscription from institutional investors [8] - Zhejiang Rongtai plans to invest RMB 20 million to establish a wholly-owned subsidiary focused on robotics [9] Group 4 - Kingood Co. has received a notification from a global leading automaker for a wheel product project in the U.S., with an estimated sales amount of approximately USD 158 million over five years [10] - Shanghai Xiba plans to purchase patents for hydrogen-electric hybrid power systems and solid-state lithium-ion battery technology, investing a total of RMB 25 million [11] - Nocare Biopharma's application for the market approval of Tafasitamab for treating relapsed/refractory DLBCL has been approved, marking a significant milestone in the market [12]

2、金固股份：收到全球龙头车企美国产乘用车车轮产品定点通知。 一、增持、股权转让、回购 1、上海莱士：控股股东海盈康拟2.5亿元-5亿元增持公司股份。 2、科德教育：公司控股股东签署了《股份转让协议》，十堰市国资委将成为公司实际控制人。 3、纳芯微：股东询价转让定价为163.15元/股。 4、盛弘股份：本次询价转让的价格为27.76元/股。 5、震有科技：拟注销105.54万股回购股份。 6、中复神鹰：鹰游集团拟向海南鹰游转让22.22%公司股份，转让价格21.02元/股。 二、对外投资、日常经营 1、万科A：与深圳地铁集团签署《不超过人民币42亿元借款合同》，并收到42亿元借款。同时约定以 不超60亿元万物云股票作为与深铁集团借款合同质押物。 晚间公告 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 3、龙旗科技：筹划发行H股股票并在香港联合交易所有限公司上市。 4、浙江荣泰：拟在浙江嘉兴投资设立全资子公司浙江荣泰智能机器人有限公司，投资金额2000万。 5、英维克：拟投资不低于10亿元建设精密温控节能设备研发中心及生产基地项目。 6、恒瑞医药：H股发行价格确定为每股44. ...